Skip to main content
Premium Trial:

Request an Annual Quote

Corvas Licenses Incyte s LifeSeq Gold Database

NEW YORK, Aug 1 –Corvas International has signed a multi-year subscription to Incyte’s LifeSeq Gold database, the companies said Wednesday.

Corvas said it would use the database for its cancer research activities. The San Diego-based company is currently researching serine proteases to determine their potential as solid tumor drug targets.

"We are integrating genome-based research with our expertise in serine protease therapeutics to expand the scope and potential proprietary position of our cancer programs," Randall Woods, CEO of Corvas, said in a statement.

"We believe access to new proteases afforded by Incyte's genomic database will facilitate our development of a leading position in the serine protease field," he said.

The LifeSeq Gold database offers information on expressed sequence tag and full-length gene sequences, mapping data, and public genomic sequence information.

Incyte of Palo Alto, Calif., did not disclose the financial terms of the non-exclusive deal.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.